GlycoMark
GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes
DIABETES MANAGEMENT Issue 15 - February 2019
Dear Healthcare Professionals,

It is our pleasure to announce complimentary access to a new online educational program for healthcare professionals caring for patients with diabetes:
Webinar:
Enhancing Diabetes Management with the GlycoMark Test
This Educational Program:
- Provides an overview of traditional tests for glycemic control
- Introduces the GlycoMark Test and related scientific and clinical evidence
- Gives insights on the practical application of the GlycoMark Test in patients with diabetes
Speaker:
Dr. Michael H. Shanik, MD, FACP, FACE
Managing Partner, Endocrine Associates of Long Island, PC
Associate Professor of Medicine, Stony Brook University Hospital
View Program Details
To integrate GlycoMark into your practice, check out the following:
- Clinical Resources (including Interpretation Guide and Compendium of Evidence)
- Product Information (including Product Sheet and Brochure)
How to Order the GlycoMark Test:
The GlycoMark test is reimbursed by most federal, state and private payers (CPT Code 84378) and available through various national and regional laboratories, and as a test kit for use on most automated chemistry instruments. Click Here for more information!
Subsequent to incorporating the GlycoMark test into clinical practice, the physician became a paid clinical consultant of GlycoMark.
This complimentary webinar is provided through the generous support of GlycoMark, Inc.
For full GlycoMark prescribing information please see our package insert.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2019 GlycoMark, Inc. All Rights Reserved. M-77-1A
GlycoMark
805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - info@glycomark.com - www.glycomark.com